Krystal Biotech to Participate in H.C. Wainwright and Guggenheim Investor Conferences

Rhea-AI Summary

Krystal Biotech (NASDAQ: KRYS) announced that its CEO, Krish S. Krishnan, will participate in two upcoming conferences: H.C. Wainwright's Gene Therapy and Gene Editing Conference on March 30, 2022, at 7:00 a.m. EDT and Guggenheim's 3rd Annual Genomic Medicines and Rare Disease Day on March 31, 2022, from 2:00 to 2:45 p.m. EDT. Webcasts of the presentations will be available, with links to access them provided in the press release. Krystal Biotech focuses on redosable gene therapy for serious diseases, leveraging proprietary technology for potential life-changing treatments.

PITTSBURGH, March 24, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc., (“Krystal”) (NASDAQ: KRYS), the leader in redosable gene therapy, today announced that Krish S. Krishnan, Chairman and Chief Executive Officer, will participate in H.C. Wainwright’s Gene Therapy and Gene Editing Conference and Guggenheim’s 3^rd Annual Genomic Medicines and Rare Disease Day.

Details for the events are as follows:

H.C. Wainwright Gene Therapy and Gene Editing Conference
Presentation Date:		Wednesday, March 30, 2022
Presentation Time:		7:00 a.m. EDT
Webcast Link:		https://journey.ct.events/view/5be9c8c9-116d-4777-b0f7-afc3aa88fd82

A webcast of the presentation will be available for 90 days beginning at 7:00 a.m. on March 30. It will also be posted in the Investors section of the Krystal Biotech website.

Guggenheim 3rd Annual Genomic Medicines and Rare Disease Day
Fireside Chat Date:		Thursday, March 31, 2022
Fireside Chat Time:		2-2:45 p.m. EDT
Webcast and Replay Link:		https://kvgo.com/guggenheim/krystal-biotech-inc-march-2022

A replay of the fireside chat will be available via a link on the Krystal Biotech website approximately 48 hours after the event and will be viewable for 1 year.

About Krystal Biotech
Krystal Biotech, Inc. (NASDAQ: KRYS) is a pivotal-stage gene therapy company leveraging its proprietary, redosable gene therapy platform and in-house manufacturing capabilities to potentially bring life-changing treatment options to patients with serious diseases, including rare diseases in skin, lung, and other areas. For more information, please visit http://www.krystalbio.com and follow @KrystalBiotech on LinkedIn and Twitter.

CONTACTS:

Investors:
Whitney Ijem
Krystal Biotech
wijem@krystalbio.com

Media:
Tiffany Hamilton
Krystal Biotech
thamilton@krystalbio.com

Source: Krystal Biotech, Inc.

FAQ

What are the details of Krystal Biotech's participation in the H.C. Wainwright Gene Therapy Conference?

Krystal Biotech's CEO will present on March 30, 2022, at 7:00 a.m. EDT, with a webcast available afterward.

When is the Guggenheim Genomic Medicines and Rare Disease Day event?

The event is scheduled for March 31, 2022, from 2:00 to 2:45 p.m. EDT.

Where can I access the webcasts of the Krystal Biotech presentations?

Webcasts can be accessed via links provided in the press release and will be available for 90 days.

What is the focus of Krystal Biotech's gene therapy technology?

Krystal Biotech focuses on redosable gene therapy, targeting serious diseases, especially rare diseases.

How can I learn more about Krystal Biotech and its projects?

For more information, visit the Krystal Biotech website or follow them on social media platforms.